How Stem Cells Are Working to Change Diabetes Treatments

Worldwide, more than 415 million people are living with diabetes. In 2012, scientists from the University of British Columbia were able to reverse diabetes in mice using stem cell transplants. Since then, stem cell therapy has been aggressively studied for its use in the treatment of and, ultimately, cure for diabetes. In clinical trials all over the country, scientists, researchers …

Cured blind man, U.S. senator crusade on Capitol Hill for stem cell innovations

WASHINGTON (MEDIA GENERAL) — The first time Doug Oliver realized just how devastatingly fast his macular degeneration had progressed was during a family road trip to New Hampshire 10 years ago. “I almost hit two pedestrians in a crosswalk,” recalled Oliver, 54. “I basically denied that I did not see them, but I knew that I hadn’t seen them.” A …

Europe approves the first stem cell-based medicinal product

The European Commission has given Holoclar®, the first advanced therapy medicinal product (ATMP) containing stem cells, conditional marketing authorisation following a recommendation for approval by the European Medicines Agency. Holoclar® uses a particular type of eye stem cell, called a limbal stem cell, to repair the cornea after injury; restoring sight. READ MORE

mature man eye exam

New research hints at stem cell treatments for cataracts

A new operating technique could spell the end of complication-prone eye surgery. A pair of unrelated studies into the efficacy of stem cell-based treatments for correcting cataracts had the scientific community abuzz on Tuesday. The studies are “amazing, almost like science fiction” Mark Daniell, head of corneal research at the Centre for Eye Research Australia in Melbourne, told Nature News. …

New Publication Elaborates on TB4’s Effects on Dry Eye Syndrome and Other Potential Ophthalmic Disorders

ROCKVILLE, Md., Aug. 12, 2015 /PRNewswire RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced a new peer-reviewed publication describing Thymosin beta 4’s (TB4) effects on dry eye syndrome and its potential value for the treatment of other ophthalmic disorders. The authors of the paper explained …